Australia's Amplia climbs as lung disorder drug shows efficacy
** Shares of Amplia Therapeutics ATX.AX rise as much as
18.2% to A$0.13, their best intraday session since Dec. 21
** Says data from a preclinical study showed that its
molecularly targeted drug, AMP945, showed efficacy while being
tested as a therapy for a type of lung fibrosis urn:newsml:reuters.com:*:nASX9yQ3pZ
** Stock hits highest level since May 23
** ATX down by a third YTD, as of last close
(Reporting by Harshita Swaminathan)
((Harshita.Swaminathan@thomsonreuters.com))
Recent news on Amplia Therapeutics
See all newsBrief: Amplia Therapeutics Signs Collaboration And Supply Agreement With Lilly
Australia's Amplia rises to 4-month high on Eli Lilly cancer drug trial collaboration
Brief: Amplia Therapeutics Says Warwick Tong Will Retire As Board Chairman
Brief: Amplia Therapeutics Reports Four Additional Complete Responses And Improved Overall Survival Data In Accent Pancreatic Cancer Trial
Brief: Amplia Therapeutics Requests Trading Halt Pending Clinical Trial Results Announcement